Current Research: Pediatric Hematology-Oncology

AALL03B1-- Classification of Acute Lymphoblastic Leukemia

Overall cure rates for children with acute lymphoblastic leukemia (ALL) now approach 80%. A key component of contemporary ALL treatment regimens is risk-based therapy. Modern risk assessment included clinical features (age and initial white blood cell count), biological characteristics of the leukemic blasts such as the presence or absence of specific genetic features, early marrow response as measured by morphology and more recently by assessment of minimal residual disease (MRD). This trial will serve as a foundation for patients with newly diagnosed ALL.

This study has two purposes:

• Special Diagnostic Tests: To identify the specific subtype of leukemia that each patient has. This will help us figure out the best treatment for each patient.
• Research Tests: To learn more about what causes leukemia and about how to improve treatment in the future. These tests are experimental. Patients will not get these test results and they will not be used in planning treatment.

Eligibility

Patients may be eligible for this trial if:

• 1-30 years of age
• Newly diagnosed acute leukemia
• ≥ 25% blasts
• Suspected acute lymphoblastic leukemia
• Entry to AALL03B1 is required for all patients in order to be eligible for entry onto a COG protocol for treatment of newly diagnosed ALL

Trial Sponsor

• Children’s Oncology Group (COG); National Cancer Institute (NCI);
  Emory University

Project Begin Date

• Feb 2005

Tentative Project End Date

• Feb 2011

Back to Pediatric Hematology-Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .